PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8K

Pacific Biosciences of California, Inc. promoted Mark Van Oene to President and CEO effective August 5, 2026, with increased compensation and a new change-in-control and severance agreement outlining enhanced severance and equity vesting terms upon qualifying terminations.

Pacific Biosciences of California, Inc. appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026, with a concurrent Board seat subject to required approvals, and adjusted his compensation to include a $743,000 annual base salary effective August 16, 2026, an annual target bonus equal to 100% of base salary under the company’s Executive Incentive Compensation Plan, and a recommended equity grant with an estimated grant-date value of $2,250,000 in the form of restricted stock units and stock options vesting over three years; in connection with this promotion, the company and Mr. Van Oene entered into a Second Amended and Restated Change in Control and Severance Agreement, effective August 5, 2026, that provides specified severance, COBRA benefits, and equity acceleration protections upon certain qualifying terminations, particularly in connection with a change in control.

Filing Facts

CIK

1299130

Ticker

-

Form

8K

Source Type

sec

Accession

0001299130-26-000117

Alert Tier

8